Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

Item
http://www.wikidata.org/entity/Q33876297
Beyond hypomethylating agents failure in patients with myelodysplastic syndromesAzacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07).Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutationsCurrent therapy of myelodysplastic syndromesTargeting DNA methylation for epigenetic therapy.Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemiaDNA methylation, isocitrate dehydrogenase mutation, and survival in gliomaClinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2)Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.Epigenetic drug discovery: targeting DNA methyltransferases.Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a reviewNovel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.Methylation of the UNC5C gene and its protein expression in colorectal cancer.Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy.
P2860

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

Item
http://www.wikidata.org/entity/Q33876297
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Report of a phase 1/2 study of ...... risk myelodysplastic syndromes
@ast
Report of a phase 1/2 study of ...... risk myelodysplastic syndromes
@en
type
label
Report of a phase 1/2 study of ...... risk myelodysplastic syndromes
@ast
Report of a phase 1/2 study of ...... risk myelodysplastic syndromes
@en
prefLabel
Report of a phase 1/2 study of ...... risk myelodysplastic syndromes
@ast
Report of a phase 1/2 study of ...... risk myelodysplastic syndromes
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Report of a phase 1/2 study of ...... risk myelodysplastic syndromes
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932